Eli Lilly and Co
NYSE:LLY
Eli Lilly and Co
NYSE:LLY
Price:
764.66 USD
-1.56%
Updated:
May 2, 2024
Eli Lilly and Co
Operating Income
|
Eli Lilly and Co
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
ZTS
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Operating Income
$3.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
See Also
What is Eli Lilly and Co's Operating Income?
Operating Income
10.3B
USD
10.3B
USD
Based on the financial report for Dec 31, 2023, Eli Lilly and Co's Operating Income amounts to 10.3B USD.
What is Eli Lilly and Co's Operating Income growth rate?
Operating Income CAGR 10Y
6%
6%
Over the last year, the Operating Income growth was 25%. The average annual Operating Income growth rates for Eli Lilly and Co have been 15% over the past three years , 12% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
